Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced participation in the following conferences during the month of November: 2020 Virtual Guggenheim Healthcare Talks | Idea Forum | Neuro/Immunology Day One-on-one meetings Monday, November 16, 2020 Virtual Fall Investor… Read More..

- Received IMPD Approval to Commence Enrollment in France for Pivotal Phase 3 Study of Galinpepimut-S in Acute Myeloid Leukemia Patients - - Strengthened Balance Sheet During Quarter with $9.2 Million Financing - NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or… Read More..

Certain assays under development are believed to be the first ever for use at the point-of-care and the first ever available in veterinary medicine ANN ARBOR, Mich., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs… Read More..